☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Fasenra
EGPA Remission with Fasenra: Michael Wechsler and Andrew Menzies Gow in Conversation with PharmaShots
May 15, 2024
AstraZeneca Reports Results of Fasenra (benralizumab) in P-III OSTRO Study for Chronic Rhinosinusitis with Nasal Polyps
September 10, 2020
AstraZeneca Receives the US FDA's Orphan Drug Designation for its First Respiratory Biologic Fasenra (benralizumab) to Treat Eosin...
August 28, 2019
AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)
April 4, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.